Vir Biotechnology, Inc. (VIR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 900M 1.8B 2.7B Q4 '18: 10.7M Q1 '19: 11.9M Q2 '19: 11.7M Q3 '19: 10.2M Q4 '19: 8.1M Q1 '20: 10.1M Q2 '20: 75.1M Q3 '20: 75.6M Q4 '20: 76.4M Q1 '21: 72.6M Q2 '21: 182.7M Q3 '21: 284.4M Q4 '21: 1.1B Q1 '22: 2.3B Q2 '22: 2.1B Q3 '22: 2.4B Q4 '22: 1.6B Q1 '23: 446.3M Q2 '23: 490.7M Q3 '23: 118.8M Q4 '23: 86.2M Q1 '24: 79.6M Q2 '24: 78.9M Q3 '24: 78.6M Q4 '24: 74.2M Q1 '25: 20.9M Q2 '25: 19M Q3 '25: 16.9M Q4 '25: 68.6M Q1 '26: 65.5M Q2 '26: 303.2M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 800M 1.6B 2.4B Q4 '20: 76.4M Q1 '21: 72.6M Q2 '21: 181.6M Q3 '21: 275.4M Q4 '21: 1B Q1 '22: 2.2B Q2 '22: 1.9B Q3 '22: 2.2B Q4 '22: 1.5B Q1 '23: 388.2M Q2 '23: 460.5M Q3 '23: 110.8M Q4 '23: 83.4M Q1 '24: 78.7M Q2 '24: 77.9M Q3 '24: 77.7M Q4 '24: 73.4M Q1 '25: 20.1M Q2 '25: 18.3M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-1.2B -600M 0 600M 1.2B 1.8B Q2 '19: -127.7M Q3 '19: -141M Q4 '19: -178M Q1 '20: -219.1M Q2 '20: -212.4M Q3 '20: -252.3M Q4 '20: -297M Q1 '21: -383.7M Q2 '21: -293.6M Q3 '21: -259.4M Q4 '21: 420.8M Q1 '22: 1.6B Q2 '22: 1.3B Q3 '22: 1.6B Q4 '22: 833.1M Q1 '23: -324.1M Q2 '23: -314.1M Q3 '23: -695.8M Q4 '23: -684.3M Q1 '24: -621M Q2 '24: -564.5M Q3 '24: -609M Q4 '24: -587.2M Q1 '25: -646.6M Q2 '25: -606.4M Q3 '25: -548.6M Q4 '25: -479.3M Q1 '26: -472.1M Q2 '26: -280.2M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-1B -500M 0 500M 1B 1.5B Q4 '18: -115.9M Q1 '19: -113M Q2 '19: -122.4M Q3 '19: -137.3M Q4 '19: -174.7M Q1 '20: -223.3M Q2 '20: -220.5M Q3 '20: -256.8M Q4 '20: -298.7M Q1 '21: -390.3M Q2 '21: -297.4M Q3 '21: -102.3M Q4 '21: 528.6M Q1 '22: 1.2B Q2 '22: 1.1B Q3 '22: 1.1B Q4 '22: 515.8M Q1 '23: -143.7M Q2 '23: -262M Q3 '23: -600.7M Q4 '23: -615.1M Q1 '24: -539.4M Q2 '24: -483M Q3 '24: -533.3M Q4 '24: -522M Q1 '25: -577.6M Q2 '25: -550.2M Q3 '25: -499.7M Q4 '25: -438M Q1 '26: -442.7M Q2 '26: -251.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

0 70M 140M 210M Q4 '20: 0 Q1 '21: 0 Q2 '21: 1.1M Q3 '21: 9M Q4 '21: 65.9M Q1 '22: 156M Q2 '22: 182.8M Q3 '22: 197.2M Q4 '22: 146.3M Q1 '23: 58.1M Q2 '23: 30.2M Q3 '23: 8M Q4 '23: 2.8M Q1 '24: 917K Q2 '24: 947K Q3 '24: 959K Q4 '24: 845K Q1 '25: 786K Q2 '25: 745K Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Operating Cash Flow TTM

-1.2B -600M 0 600M 1.2B 1.8B Q3 '19: -120.3M Q4 '19: -129.6M Q1 '20: -148.6M Q2 '20: -134.9M Q3 '20: -147.8M Q4 '20: -190.9M Q1 '21: -232.1M Q2 '21: -81.4M Q3 '21: -137.3M Q4 '21: -47.6M Q1 '22: 592M Q2 '22: 1.4B Q3 '22: 1.6B Q4 '22: 1.7B Q1 '23: 987.4M Q2 '23: -362M Q3 '23: -635.7M Q4 '23: -778.8M Q1 '24: -762.4M Q2 '24: -451M Q3 '24: -466.6M Q4 '24: -446.4M Q1 '25: -415.1M Q2 '25: -457.4M Q3 '25: -453.5M Q4 '25: -391.8M Q1 '26: -446.1M Q2 '26: -202.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-1.2B -600M 0 600M 1.2B 1.8B Q3 '19: -130.4M Q4 '19: -138.6M Q1 '20: -155.3M Q2 '20: -140.3M Q3 '20: -153.4M Q4 '20: -197.5M Q1 '21: -238M Q2 '21: -88M Q3 '21: -148.5M Q4 '21: -69.4M Q1 '22: 555M Q2 '22: 1.4B Q3 '22: 1.6B Q4 '22: 1.6B Q1 '23: 928.4M Q2 '23: -409.9M Q3 '23: -668.3M Q4 '23: -800.4M Q1 '24: -779M Q2 '24: -458.8M Q3 '24: -473.5M Q4 '24: -453.7M Q1 '25: -422.1M Q2 '25: -466.4M Q3 '25: -460M Q4 '25: -396.6M Q1 '26: -449.6M Q2 '26: -203.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '20: 115M Q3 '20: 125.8M Q1 '21: 127.7M Q2 '21: 133.8M Q3 '21: 133.9M Q1 '22: 134.5M Q2 '22: 132.5M Q3 '22: 135M Q1 '23: 133.6M Q2 '23: 134.1M Q3 '23: 134.3M Q1 '24: 135.3M Q2 '24: 136.2M Q3 '24: 136.7M Q1 '25: 137.5M Q2 '25: 138.4M Q3 '25: 138.9M Q1 '26: 147.4M Q2 '26: 168.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '18: -15.32 Q1 '19: -13.75 Q2 '19: -14.04 Q3 '19: -14.48 Q4 '19: -12.14 Q1 '20: -9.66 Q2 '20: -6.29 Q3 '20: -2.36 Q4 '20: -2.48 Q1 '21: -3.09 Q2 '21: -2.36 Q3 '21: -0.87 Q4 '21: 3.90 Q1 '22: 9.07 Q2 '22: 8.03 Q3 '22: 8.51 Q4 '22: 3.83 Q1 '23: -1.08 Q2 '23: -1.95 Q3 '23: -4.47 Q4 '23: -4.59 Q1 '24: -4.01 Q2 '24: -3.58 Q3 '24: -3.92 Q4 '24: -3.82 Q1 '25: -4.22 Q2 '25: -4.00 Q3 '25: -3.61 Q4 '25: -3.15 Q1 '26: -3.12 Q2 '26: -1.85 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.